Taylor Wessing advised Shield Therapeutics on securing $26 million debt and equity fundraising. Shield Therapeutics plc, a specialty pharmaceutical company listed on AIM, has secured a...
Shield Therapeutics’ $26m Debt and Equity Fundraising
Shield Therapeutics plc’s Transformational Collaboration Agreement With Viatris
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, concluded its transformational collaboration agreement with global...
Shield Therapeutics plc’s Debt and Equity Fundraise
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, extended an existing convertible debt facility by $10...